Phase I Study to Investigate the Safety, Tolerability and Pharmacodynamic Effects of Sublingual Immunotherapy Tablets Given in Single Rising Doses and in Multi Dose Regimens to Subjects With an Allergy to Ragweed Pollen.
Phase of Trial: Phase I
Latest Information Update: 26 Jul 2017
At a glance
- Drugs Ragweed allergy immunotherapy (Primary)
- Indications Allergic rhinitis
- Focus Adverse reactions
- Sponsors Stallergenes SA
- 26 Jul 2017 Last checked against ClinicalTrials.gov record.
- 26 Oct 2010 New trial record